Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (84)	6/16/2002 10:12:15 PM
From: keokalani'nui	Respond to of 130

Medigene Discontinues Etomoxir Development Definitively MUNICH -(Dow Jones)- German biotechnology company Medigene AG (G.MDG) said Friday it has decided to discontinue the development of its congestive heart failure drug Etomoxir because Phase II clinical data showed it didn't have the expected efficacy. In April, the company prematurely halted the clinical trials due to raised liver enzymes in around 5% of the patients tested with a 40 milligram or 80 milligram dosage. It had planned to continue the trials with a lower dosage, but was awaiting the results of the Phase II data to determine whether the program was still worth pursuing. Etomoxir is one of seven products in Medigene's pipeline.